Core Insights - Several small-cap biotech and therapeutics companies experienced significant gains in after-hours trading, driven by earnings updates, financial guidance, and regulatory developments [1] Company Summaries - Inotiv, Inc. (NOTV) saw a 36.61% increase in after-hours trading to $0.94, recovering from a 33.20% decline at the close, following preliminary Q4 revenue expectations of $137.5 million to $138.5 million and full-year revenue projections of $512.5 million to $513.5 million [2] - Applied Therapeutics, Inc. (APLT) rose 16.89% to $0.33 after a 30.19% gain at the close, with investors reacting positively to a narrower Q3 net loss of $19.0 million, or $0.13 per share, compared to a $68.6 million loss, or $0.48 per share, in the same quarter last year [3] - Alumis Inc. (ALMS) advanced 7.09% to $5.97, despite reporting a Q3 net loss of $110.8 million, wider than the $93.1 million loss in the prior year, with $2.1 million in collaboration income potentially boosting investor confidence [4] - TELA Bio, Inc. (TELA) increased 7.89% to $1.23 after a 14.08% gain at the close, reporting a reduced Q3 net loss of $8.6 million compared to $10.4 million a year earlier, with revenue growth of 9% to $20.7 million and revised 2025 guidance projecting at least 16% revenue growth over 2024 [5] - Corcept Therapeutics Inc. (CORT) gained 4.90% to $78.80, reflecting continued investor interest despite no specific news released [6] - BioRestorative Therapies, Inc. (BRTX) jumped 8.06% to $1.34, rebounding from a 6.77% decline at the close, following the announcement of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application pathway for its BRTX-100 program [7]

Group 1: Applied Therapeutics, Inc. (APLT) - The stock price of Applied Therapeutics rose to $0.35 due to developments in products targeting cardiovascular disease and diabetic complications [1] - The company faces uncertainties regarding FDA approval for its lead drug, which may lead to a decline in stock price [1] - Trading volume surged to over 20 million, significantly higher than the average of 4.88 million [1][5] Group 2: Alpha Technology Group Limited (ATGL) - Alpha Technology Group's stock price increased to $16.98, driven by its focus on cloud-based IT services and AI-powered solutions [2] - A strategic partnership with AB DAO aims to enhance AI and blockchain technology in supply chain management and IoT, boosting investor confidence [2] Group 3: WeShop Holdings Limited (WSHP) - WeShop's stock price rose to $48 following its debut on the Nasdaq Capital Market [3] - The company integrates social interactions with shopping, enhancing product discovery and retailer growth [3] - WeShop plans to launch its app in the U.S., partnering with retailers and offering users ownership in the company [3] Group 4: Market Trends - The movements in stock prices reflect diverse sectors, with companies under close scrutiny by investors and analysts for growth opportunities and market impacts [4][5]

Core Insights - The after-hours trading session on November 14, 2025, saw significant movements in biotech and therapeutics stocks due to various corporate updates and financial results [1] Company Summaries - Repare Therapeutics Inc. (RPTX) experienced a 30.32% increase, closing at $2.15, following the announcement of a definitive agreement for acquisition by XenoTherapeutics, with shareholders set to receive $1.82 per share plus a contingent value right. The company reported cash and cash equivalents of $112.6 million as of September 30, 2025, up from $109.5 million at the end of June [2] - Senti Biosciences, Inc. (SNTI) rose 7.45% to $1.73 after reporting a net loss of $18.1 million, or $0.69 per share, for Q3 2025. Cash and cash equivalents decreased to $12.2 million from $48.3 million at year-end 2024 [3] - Applied Therapeutics, Inc. (APLT) advanced 8.15% to $0.24, reporting a net loss of $19.0 million, or $0.13 per share, for Q3 2025, an improvement from a net loss of $68.6 million, or $0.48 per share, in the same period of 2024. Cash and cash equivalents totaled $11.9 million, down from $79.4 million at the end of 2024 [4] - RenovoRx, Inc. (RNXT) climbed 6.28% to $0.80, reporting revenues of approximately $266,000 for Q3 2025, with a net loss of $2.9 million compared to $2.5 million in the same period of 2024 [5] - Nuvalent, Inc. (NUVL) gained 9.33%, closing at $105.50, and announced plans for a webcast to discuss pivotal data for its investigational ALK-selective inhibitor in patients with advanced ALK-positive non-small cell lung cancer [6]

Company Performance - JD.com reported a quarterly revenue growth of 14.9% year-over-year to $42.01 billion, surpassing the analyst consensus estimate of $41.33 billion [2] - JD posted an adjusted net income per ADS of 52 cents, exceeding the analyst consensus estimate of 34 cents [2] Stock Movements - Mersana Therapeutics Inc shares surged 205% to $27.06 after announcing its acquisition by Day One Biopharmaceuticals [8] - Nuvve Holding Corp shares increased 215% to $0.4916 following an aggregation agreement in Japan [8] - Ondas Holdings Inc shares rose 24% to $6.82 after reporting better-than-expected third-quarter results and raising its FY25 sales guidance [8] - Korro Bio Inc shares dropped 79% to $6.48 after announcing a wind-down of research and development activities [8] - Applied Therapeutics Inc shares fell 44% to $0.5070 following third-quarter results [8] - EPWK Holdings Ltd shares decreased 33% to $0.0434 after announcing a 40-for-1 share consolidation effective November 17 [8]

Company Performance - JD.com reported a quarterly revenue growth of 14.9% year-over-year to $42.01 billion, surpassing the analyst consensus estimate of $41.33 billion [2] - JD posted an adjusted net income per ADS of 52 cents, exceeding the analyst consensus estimate of 34 cents [2] Stock Movements - Mersana Therapeutics Inc shares surged 205% to $27.06 after announcing its acquisition by Day One Biopharmaceuticals [8] - Nuvve Holding Corp shares increased 215% to $0.4916 following an aggregation agreement in Japan [8] - Ondas Holdings Inc shares rose 24% to $6.82 after reporting better-than-expected third-quarter results and raising its FY25 sales guidance [8] - Korro Bio Inc shares dropped 79% to $6.48 after announcing a wind-down of research and development activities [8] - Applied Therapeutics Inc shares fell 44% to $0.5070 following third-quarter results [8] - EPWK Holdings Ltd shares decreased 33% to $0.0434 after announcing a 40-for-1 share consolidation effective November 17 [8]

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between Ryerson Holding Corporation and Olympic Steel, Inc. for Ryerson shareholders, as they will own approximately 63% of the combined entity upon completion of the transaction [1]. Group 1: Investigation Details - The investigation focuses on whether Ryerson and its board violated federal securities laws or breached fiduciary duties by not obtaining the best possible consideration for shareholders and failing to disclose all material information necessary for assessing the merger [3]. - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [4]. Group 2: Legal Rights and Contact Information - Ryerson shareholders are encouraged to contact Halper Sadeh LLC to learn about their legal rights and options regarding the merger [2]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [4].

Company Developments - Innovation Beverage Group Limited (NASDAQ:IBG) experienced a 312% surge in stock price to $2.37, driven by strategic expansion in the beverage sector and a potential merger with BlockFuel Energy Inc. [2] - bioAffinity Technologies, Inc. (BIAFW) saw a 265% jump in stock price to $0.28, linked to the release of three new case studies demonstrating the clinical value of its product, CyPath® Lung, in detecting early-stage lung cancer [3] - MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) recorded a 116% rise in stock price to $3.13, attributed to the adoption of its REMONY system by the Japan Ground Self-Defense Force [4] - Applied Therapeutics, Inc. (APLT) experienced a 71% increase in stock price to $0.95, driven by progress in clinical trials for its lead product candidate AT-007 and advancements in the CMT-SORD program [5] Market Trends - Recent market trends indicate significant price changes for several companies, reflecting key developments and heightened investor interest [1] - The dynamic nature of the stock market is underscored by how company developments and investor sentiment can significantly influence stock prices [6]

Core Insights - The company is advancing its CMT-SORD program and has scheduled a meeting with the FDA in Q3 2025 to discuss the New Drug Application (NDA) submission for govorestat [1][4] - Full 12-month clinical results from the INSPIRE Phase 2/3 trial of govorestat for CMT-SORD were presented, showing slowed disease progression observed via MRI at 24 months [1][4] - A new sponsored Sorbitol Assay has been launched to assist in identifying patients suspected of having CMT-SORD [1][4] - The company has entered into an out-licensing agreement with Biossil, Inc. for AT-001, an investigational therapy for Diabetic Cardiomyopathy [1][9] CMT-SORD Program - A meeting with the FDA is planned to align on the NDA submission strategy for govorestat, focusing on comprehensive data for Sorbitol Dehydrogenase Deficiency [4] - The newly launched Urine Sorbitol Assay aims to support healthcare providers in identifying suspected CMT-SORD cases at no cost to patients [4] - Clinical results from the INSPIRE trial indicated that govorestat was generally safe and well-tolerated, with significant improvements in key secondary endpoints at 12 months [4] Other Development Programs - New data on govorestat for PMM2-CDG will be presented at the 2025 ASHG Annual Meeting [2][6] - The review of the govorestat development program for Classic Galactosemia is progressing as planned, including responses to the Complete Response Letter from the FDA [5] Financial Performance - As of June 30, 2025, cash and cash equivalents totaled $30.4 million, down from $79.4 million at the end of 2024 [8] - Research and development expenses for Q2 2025 were $9.9 million, slightly down from $10.0 million in Q2 2024 [8] - General and administrative expenses increased to $13.2 million in Q2 2025 from $10.6 million in Q2 2024 [8] - The net loss for Q2 2025 was $21.3 million, compared to a net income of $2.9 million in Q2 2024 [8][15]

Core Viewpoint - Applied Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, highlighting key leadership appointments and ongoing development programs for its lead drug candidate, govorestat, aimed at addressing unmet medical needs in rare diseases [1][2]. Leadership Appointments - John H. Johnson was appointed as Executive Chairman, and Les Funtleyder was named Interim Chief Executive Officer [5]. - Todd F. Baumgartner, MD, MPH was appointed as Chief Regulatory Officer, and Reena Thomas Colacot was appointed as Vice President and Head of Quality [5]. Development Programs - The company is focused on regulatory interactions regarding govorestat for Classic Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency [2]. - A Complete Response Letter (CRL) was received from the FDA for the NDA submitted for govorestat for Classic Galactosemia, and the company is evaluating its response [5]. Financial Results - Cash and cash equivalents increased to $79.4 million as of December 31, 2024, from $49.9 million at the end of 2023 [5]. - Research and development expenses decreased to $48.7 million in 2024 from $53.9 million in 2023, primarily due to reduced clinical and drug manufacturing costs [5]. - General and administrative expenses rose to $56.0 million in 2024 from $20.6 million in 2023, largely due to increased commercial and legal expenses [5]. - The net loss for 2024 was $105.6 million, or $0.76 per share, compared to a net loss of $119.8 million, or $1.42 per share, in 2023 [5][12]. Revenue Overview - Total revenue for 2024 was $455,000, a decrease from $9.99 million in 2023, with no license revenue reported for the year [12].

Core Viewpoint - Applied Therapeutics, Inc. has filed a Form 12b-25 with the SEC for a late filing of its Annual Report on Form 10-K for fiscal year 2024, granting an automatic 15-day extension to file the report by April 15, 2025 [1] Company Overview - Applied Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel drug candidates targeting validated molecular pathways in rare diseases [3] - The lead drug candidate, govorestat, is an Aldose Reductase Inhibitor designed for treating central nervous system rare metabolic diseases, including Classic Galactosemia, SORD Deficiency, and PMM2-congenital disorder glycosylation [3] Filing Details - The Form 12b-25 allows the company additional time to finalize its financial statements, with the expectation to file the Form 10-K by April 15, 2025 [1] - The filing is accessible on the company's Investor Relations website under "SEC Filings" [2] - A subsequent announcement will be made to disclose the fourth quarter and full-year 2024 earnings results once the Form 10-K filing date is confirmed [2]